One for All?

Exploring the Need for Country Specific Value Sets for Preference-Based Measures of Health

UIC HTA 132

Su N¹, Kuharic M², Yu J¹, Cella D², Pickard AS¹

¹University of Illinois-Chicago College of Pharmacy, Department of Pharmacy Systems, Outcomes, and Policy ²Northwestern University, Feinberg School of Medicine

INTRODUCTION

- HTA guidelines often recommend local or country-specific value sets for preference-based measures of health, which are developed through surveys among local or specific country population, to reflect unique health priorities and preferences in diverse population. 1,2
- Standardized protocols for the conduct of valuation studies have been developed enhancing the quality recent years, and methodological consistency in value sets across countries and the ability to compare preferences for attributes of health based on country/culture.3,4,5
- Given the standardization of study designs, if value sets are shown to be similar across countries, **fewer** valuation studies may be needed.

OBJECTIVE

To explore the need for unique value sets in culturally similar countries for preference-based measures of health.

METHOD

- Value Sets: FACT-8D value sets from US, Canada, and Australia. 4,8,9
- Sample: Secondary analysis of cross-sectional data collected from 543 cancer patients who participated in a validation study of cancer symptoms scales.⁶
- Measures: Each participant completed the Functional Assessment of Cancer Therapy (FACT) questionnaire that included items that comprise the FACT-8D, a descriptive system that includes 8 dimensions closely related to quality-of-life of cancer patients. Performance status was evaluated with the Eastern Cooperative Oncology Group (ECOG) by both the physician and the patient.⁷
- Statistical Analysis
 - Value sets were compared using ranking of coefficients; by comparing empirical tests on dataset using known groups comparisons based on ECOG status.
 - Analysis of Variance (ANOVA) was used to compare discriminative ability of FACT-8D index scores across ECOG levels.
 - Discriminative power of Canadian and Australian, relative to the US value set, were quantified by relative efficiency (RE) ratios.
 - RE = 1: similar efficiency versus US value set
 - RE > 1: less efficient versus US value set
 - RE < 1: more efficient versus US value set

RESULTS

- Similar order of importance among the 8 dimensions of FACT-8D was observed (pain then nausea had the highest disutility consistently among three country value sets), with slight reordering in some dimensions (fatigue and worry in Canadian vs US and Australian value set) (Fig 1)
- Utility scores showed very similar statistical efficiency based on known groups comparisons using ECOG for US (F=25.5) Canada (F=27.1) and Aus (F=24.4).

TABLE 1: Respondent Characteristics

Overall Sample (n=534) **Characteristics** Age (mean, standard deviation) 59 (12) Gender – female (n, %) 258 (48%) Race (n, %) 474 (89%) White Black 44 (8%) Other 15 (3%) Of Spanish/Hispanic Ancestry 16 (3%) **ECOG Level** 132 (25%) 263 (49%) 76 (14%) 15 (3%)

FIGURE 1: Level 4 Ranking of Disutility in Each Dimension by Country Value Sets





FIGURE 2: Mean Utility Values for Physician ECOG



Value Set	ECOG=0	ECOG=1	ECOG=2	ECOG=3	F-Stat	RE
US	0.78	0.69	0.59	0.45	25.47	Reference
Canadian	0.72	0.6	0.48	0.3	27.08	1.06
Australian	0.74	0.63	0.53	0.37	24.42	0.96

DISCUSSION

- The results of this study suggest that a single value set could be considered an option for culturally similar countries if resource constraints exist. This evidence could inform future HTA policies about countries that could be considered potential substitutes or combined in super studies for emerging preference-based measures.
- Additional evidence would be helpful to test the robustness of these findings using multiple country value sets for other measures like the EQ-5D and QLU-C10D based on the EORTC.

REFERENCES

- 1. National Institute for Health and Care Excellence (NICE) [UK]. 2022. NICE health technology evaluations: the manual. https://www.nice.org.uk/process/pmg36/chapter/economic-evaluation. Accessed 30 September 2024 2. Zorginstituut Nederland (ZiN) [Netherlands]. Guideline for economic evaluations in healthcare. 2024. https://english.zorginstituutnederland.nl/about-us/working-methods-and-procedures/guideline-for-economic-evaluations-in-Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17(4):445-453. doi:10.1016/j.jval.2014.04.002
- King MT, Norman R, Mercieca-Bebber R, Costa DSJ, McTaggart-Cowan H, Peacock S, Janda M, Müller F, Viney R, Pickard AS, Cella D; Multi-Attribute Utility in Cancer Consortium. The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. Value Health. 2021 Jun;24(6):862-873. doi: 10.1016/j.jval.2021.01.007. Epub 2021 May 7. Erratum in: Value Health. 2024 Jun 21:S1098-3015(24)02410-0. doi: 10.1016/j.jval.2024.06.001. PMID: 34119085. King MT, Costa DS, Aaronson NK, et al. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30 [published correction appears in Qual Life Res. 2016 Oct;25(10):2683. doi: 10.1007/s11136-016-1260-3]. Qual Life Res. 2016;25(3):625-636. doi:10.1007/s11136-015-1217-y
- Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer [published correction appears in Health Qual Life Outcomes. 2010;8:4]. Health Qual Life Outcomes. 2007;5:70. Published 2007 Dec 21. doi:10.1186/1477-7525-5-70 Azam F, Latif MF, Faroog A, Tirmazy SH, AlShahrani S, Bashir S, Bukhari N. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Case Rep Oncol. 2019 Sep 25;12(3):728-736. doi: 10.1159/000503095. PMID: 31616281; PMCID: PMC6792426.
- 8. King MT, Revicki DA, Norman R, Müller F, Viney RC, Pickard AS, Cella D, Shaw JW; MAUCa Consortium. United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument. Pharmacoecon Open. 2024 Jan;8(1):49-63. doi: 10.1007/s41669-023-00448-5. Epub 2023 Dec 7. PMID: 38060096; PMCID: PMC10781923.
- McTaggart-Cowan H, King MT, Norman R, Costa DSJ, Pickard AS, Viney R, Peacock SJ; Canadian MAUCa Team. The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study. Health Qual Life Outcomes. 2022 Jun 16;20(1):97. doi: 10.1186/s12955-022-02002-z. PMID: 35710417; PMCID: PMC9205108.

